Drug Profile
MK 1496
Alternative Names: MK-1496Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Japan (PO)
- 07 Jun 2011 Interim efficacy, adverse events & pharmacokinetics data from a phase I trial in Solid tumours presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO-2011)
- 26 May 2009 Phase-I clinical trials in Solid tumours in Japan (PO)